Clinical importance of thromboembolic disease in mesothelioma patients

Postgraduate Thesis uoadl:2838552 313 Read counter

Unit:
Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences
Deposit date:
2018-12-29
Year:
2018
Author:
Basdeki Aikaterini
Supervisors info:
Κωνσταντίνος Ν. Συρίγος, Καθηγητής, Ιατρική, ΕΚΠΑ, Επιβλέπων
Πέτρος Μπακάκος, Αναπληρωτής Καθηγητής, Ιατρική, ΕΚΠΑ
Νικολέτα Ροβίνα, Επίκουρη Καθηγήτρια, Ιατρική, ΕΚΠΑ
Original Title:
Κλινική σημασία της θρομβοεμβολικής νόσου σε ασθενείς με μεσοθηλίωμα
Languages:
Greek
Translated title:
Clinical importance of thromboembolic disease in mesothelioma patients
Summary:
Malignant Mesothelioma (MM) is an aggressive form of cancer originating from mesothelial cells primarily of the pleura, but also of the peritoneal, pericardial and testicular epithelium.
Thromboembolic disease (DVT, PE) is a serious disease entity, with a population-wide incidence of 1-2 episodes per 1000 individuals per year and many times leads the patient to death.
Purpose: Considering the high incidence and predictive value of thromboembolic events in cancer patients, the aim of the study is to investigate the incidence of thromboembolic events in patients with mesothelioma, epidemiological data, known risk factors for thromboembolic events and anticoagulation. and prognostic survival factors.
Method: To study the patients with malignant mesothelioma on the Oncology Unit of the Clinic of the Hospital "SOTIRIA" from 9/2006 to 3/2017, aiming at the recording and study of thromboembolic events presented by the patients.
Results: Of the 131 patients with malignant mesothelioma, four patients with malignant mesothelioma (3.1%) developed a thromboembolic event, of which 3 (75.0%) and 1 (25%) female, with an average age of 71 years. Half were exposed to asbestos. Sarcomatous mesothelioma was the most common histological type (25%) and for the rest (19.7%) the histological type was not identified. Deep vein thrombosis showed 50% of patients, pulmonary embolism was 25%, and 25% of patients had both. The most frequent location of deep vein thrombosis is the lower extremities (50%).
In 25% of cases with pulmonary embolism, deep venous thrombosis was predominantly at the upper extremity. All patients with thrombosis were diagnosed after having diagnosed malignancy. Half in Stage II and Stage III and IV respectively. 75% of patients with thrombosis had another concomitant disease. The time from diagnosis to treatment initiation was 50.7 days for patients without thrombosis and 77.3 days with thrombosis patients, respectively.
Progressive disease and death rates were similar in both groups. In 50% of patients with thrombosis, the diagnosis of the disease occurred after a closed pleural biopsy, while in the non-diagnostic patients that seem to prevail is open biopsy-thoracotomy (28.8%) and openlabel VATS (22.4%), 99% of patients with thrombosis episode received chemotherapy, 50% radiotherapy (25% radical and 25% prophylactic), 25% pleurodesis. All of them received supportive treatment with growth factors. Tinzaparin was taken by all patients to treat thromboembolic events.
Conclusion: Malignant mesothelioma has a small percentage of thromboembolic disease, mainly related to the histological type of mesothelioma, advanced stage of the disease and the use of growth factors.
Main subject category:
Health Sciences
Keywords:
Asbestos, Biomarkers, Thromboembolic disease, Malignant mesothelioma
Index:
No
Number of index pages:
0
Contains images:
Yes
Number of references:
60
Number of pages:
74
File:
File access is restricted only to the intranet of UoA.

ΚΛΙΝΙΚΗ ΣΗΜΑΣΙΑ ΤΗΣ ΘΡΟΜΒΟΕΜΒΟΛΙΚΗΣ ΝΟΣΟΥ ΣΕ ΑΣΘΕΝΕΙΣ ΜΕ ΜΕΣΟΘΗΛΙΩΜΑ.pdf
399 KB
File access is restricted only to the intranet of UoA.